EyeCon 2022: Management options for the treatment of pediatric myopia
December 17th 2022Jefferson Doyle, MBBCh, MD, PhD, MHS, of the Wilmer Eye Institute at Johns Hopkins University School of Medicine, addresses myopic concerns, such as public health measures including time outdoors, as well as pharmacological approaches including the current atropine data that has been completed and ongoing studies.
EyeCon 2022: Ophthalmology Times co-chairs discuss highlights of Day 1
December 17th 2022Ophthalmology Times®' EyeCon co-chairs Peter J. McDonnell, MD, director of the Wilmer Eye Institute, and glaucoma specialist Oluwatosin U. Smith MD, from Glaucoma Associates of Texas, discuss some of the highlights of EyeCon 2022.
EyeCon 2022: Important updates in retinopathy of prematurity for clinicians
December 17th 2022Julius Oatts, MD, covered a range of current considerations for retinopathy of prematurity (ROP), including the updated International Classification for ROP, clinical research, and some of the socioeconomic factors that affect ROP. Oatts is assistant professor and associate residency program director with the Department of Ophthalmology at the University of California, San Francisco.
BRIM Biotechnology receives FDA orphan drug designation for treatment of neurotrophic keratitis
December 8th 2022Receiving FDA orphan drug designation allows the company to proceed with plans to advance the development of BRM424, a novel, first-in-class, potential treatment for neurotrophic keratitis.
New potential mechanism for vision loss discovered
December 6th 2022Researchers from the Deutsches Zentrum für Neurodegenerative Erkrankungen and the Center for Regenerative Therapies Dresden at TU Dresden have found that visual cells in the human retina may not simply die in some diseases, but are mechanically transported out of the retina beforehand.
Retinal cells may have potential to protect themselves from diabetic retinopathy
December 5th 2022According to researchers, cells within retinal blood vessels are endowed with a previously unappreciated ability to acquire resistance against the damaging effects of hyperglycemia in patients with diabetes mellitus.
SparingVision’s lead asset SPVN06 clears IND application in US for treatment of retinitis pigmentosa
December 4th 2022SPVN06 is a breakthrough gene therapy approach aimed at stopping or slowing disease progression in patients affected by IRDs and dry age-related macular degeneration (AMD), regardless of their genetic background.